Purdue Research Foundation

Richard M Van Rijn

Daniel Patrick Flaherty

Val J Watts

Jatinder Kaur

Mark Stanley Cushman

Markus Lill

Mohamed S A Elsayed

Robert J Cassell

Jason A Scott

Amr Hamed Mahmoud Abdallah

The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

Pyrazolyl pyrimidinone compounds and the uses thereof

The present disclosure relates to novel &#x3b4;-opioid receptor agonists, and the method of making and using the novel &#x3b4;-opioid receptor agonists. The novel &#x3b4;-opioid receptor agonists are selective &#x3b4;-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel &#x3b4;-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.

Delta-opioid receptor agonists

Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence

This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors, compounds having a formula or a pharmaceutically acceptable salt thereof, as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.

Adenylyl cyclase inhibitors for chronic pain and opioid dependence

Growing community of inventors

West Lafayette, IN, United States of America

Richard M Van Rijn